Dr. Bozik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2100 Wharton St
Ste 615
Pittsburgh, PA 15203Phone+1 412-488-1776Fax+1 412-488-8487
Education & Training
UPMC Medical Education (Pittsburgh)Residency, Neurology, 1990 - 1992- UPMC Medical EducationResidency, Pathology-Anatomic and Clinical, 1989 - 1990
University of MichiganResidency, Neurology, 1988 - 1989- UPMC Medical Education (Mercy)Internship, Transitional Year, 1987 - 1988
University of Pittsburgh School of MedicineClass of 1987
Certifications & Licensure
PA State Medical License 1989 - 2014- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 54 citationsAssociation Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Late...Jinsy A. Andrews, Lisa Meng, Sarah Kulke, Stacy A. Rudnicki, Andrew A. Wolff
JAMA Neurology. 2018-01-01 - 42 citationsA post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS.Michael E. Bozik, Hiroshi Mitsumoto, Benjamin Rix Brooks, Stacy A. Rudnicki, Dan Moore
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2014-08-20 - 174 citationsDexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialMerit Cudkowicz, Leonard H. van den Berg, Jeremy M. Shefner, Hiroshi Mitsumoto, Jesus S. Mora
The Lancet. Neurology. 2013-11-01
Press Mentions
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)February 28th, 2022- Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating That Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung FunctionSeptember 7th, 2021
- Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021May 17th, 2021
- Join now to see all
Grant Support
- Therapeutic Studies--Primary CNS MalignanciesNational Cancer Institute1996–1997
- Immunobiological Responses To RAT Brain Tumor VaccinesNational Cancer Institute1996–1997
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
